AC Immune SA, a Swiss drug developer focused on Alzheimer´s disease, has raised CHF 40 million ($34.6m) in Series C funding. No investors were identified, except that they were existing shareholders in the company.
AC Immune SA, a Swiss drug developer focused on Alzheimer´s disease, has raised CHF 40 million ($34.6m) in Series C funding. No investors were identified, except that they were existing shareholders in the company.
